RECRUITING

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to reduce the exposure of broad-spectrum antimicrobials by optimizing the rapid detection of CAP pathogens and improving rates of de-escalation following negative cultures. To accomplish this, we will perform a 3-year, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms: a) rapid diagnostic testing b) pharmacist-led de-escalation c) rapid diagnostic testing + pharmacist-led de-escalation and d) usual care

Official Title

Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia

Quick Facts

Study Start:2022-11-01
Study Completion:2026-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05568654

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. 1. Admission to intensive care unit within 24 hours of hospital admission
  2. 2. Comfort care measures only
  3. 3. Cystic fibrosis
  4. 4. Discharged from an acute care hospital in the past week
  5. 5. Patients not eligible for empiric therapy due to a known pathogen (any positive blood or respiratory cultures in the 72 hours prior to admission)

Contacts and Locations

Study Contact

Michael Rothberg, M.D.
CONTACT
216-445-0719
ROTHBEM@ccf.org
Abhishek Deshpande, M.D., PhD
CONTACT
216-445-6207
DESHPAA2@ccf.org

Principal Investigator

Michael Rothberg, M.D.
PRINCIPAL_INVESTIGATOR
The Cleveland Clinic

Study Locations (Sites)

Indian River Hospital
Vero Beach, Florida, 32960
United States
Weston Hospital/Cleveland Clinic Florida
Weston, Florida, 33331
United States
Akron General Hospital
Akron, Ohio, 44307
United States
Avon Hospital
Avon, Ohio, 44011
United States
Lutheran Hospital
Cleveland, Ohio, 44113
United States
Cleveland Clinic Main Campus
Cleveland, Ohio, 44195
United States
Euclid Hospital
Euclid, Ohio, 44119
United States
Fairview Hospital
Fairview Park, Ohio, 44111
United States
Marymount Hospital
Garfield Heights, Ohio, 44125
United States
Hillcrest Hospital
Mayfield Heights, Ohio, 44124
United States
Medina Hospital
Medina, Ohio, 44256
United States
South Pointe Hospital
Warrensville Heights, Ohio, 44122
United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

  • Michael Rothberg, M.D., PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-01
Study Completion Date2026-06-30

Study Record Updates

Study Start Date2022-11-01
Study Completion Date2026-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Community-Acquired Pneumonia
  • Antimicrobial Stewardship
  • Point-of-Care Testing